Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Trial Profile

A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Momelotinib (Primary) ; Ruxolitinib
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms Simplify 1
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 03 Dec 2018 Results presented in the Sierra Oncology media release.
    • 03 Dec 2018 According to a Sierra Oncology media release, results from this study are being presented today at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition.
    • 27 Nov 2018 According to a Sierra Oncology media release, results from this study will be presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top